Abstract
Interest in the effectiveness of psychological interventions in patients with psychosis has increased in the last 2 decades, and early intervention programs are increasingly common. PIENSA (Programa de Intervención en Psicosis Adolescente; Intervention Program for Adolescent Psychosis) is a clinical program and pilot study based on previous research into the efficacy of early intervention in preventing relapse and improving outcome in patients with first-episode psychosis.
We describe a psychoeducational intervention designed for adolescents with early-onset psychosis and their parents. The intervention is adapted from McFarlane’s Multiple Family Therapy model to our setting and population (adolescents treated in the Spanish public health system). It consists of 2 stages: an individual stage comprising 3 sessions and a subsequent group stage comprising 12 sessions. The total program lasts for 1 academic year (9 months).
We present the design of our program and our preliminary experience in a Child and Adolescent Unit in Spain.
Keywords: Adolescents, family intervention, group therapy, psychoeducational, psychosis, treatment.
Adolescent Psychiatry
Title:PIENSA: Development of an Early Intervention Program for Adolescents With Early-Onset Psychosis and Their Families
Volume: 2 Issue: 3
Author(s): Ana Ruiz-Sancho, Ana Calvo, Marta Rapado-Castro, Miguel Moreno, Carmen Moreno, Teresa Sanchez-Gutierrez, Cecilia Tapia, Guadalupe Chiclana, Pamela Rodriguez, Patricia Fernandez, Celso Arango and Maria Mayoral
Affiliation:
Keywords: Adolescents, family intervention, group therapy, psychoeducational, psychosis, treatment.
Abstract: Interest in the effectiveness of psychological interventions in patients with psychosis has increased in the last 2 decades, and early intervention programs are increasingly common. PIENSA (Programa de Intervención en Psicosis Adolescente; Intervention Program for Adolescent Psychosis) is a clinical program and pilot study based on previous research into the efficacy of early intervention in preventing relapse and improving outcome in patients with first-episode psychosis.
We describe a psychoeducational intervention designed for adolescents with early-onset psychosis and their parents. The intervention is adapted from McFarlane’s Multiple Family Therapy model to our setting and population (adolescents treated in the Spanish public health system). It consists of 2 stages: an individual stage comprising 3 sessions and a subsequent group stage comprising 12 sessions. The total program lasts for 1 academic year (9 months).
We present the design of our program and our preliminary experience in a Child and Adolescent Unit in Spain.
Export Options
About this article
Cite this article as:
Ruiz-Sancho Ana, Calvo Ana, Rapado-Castro Marta, Moreno Miguel, Moreno Carmen, Sanchez-Gutierrez Teresa, Tapia Cecilia, Chiclana Guadalupe, Rodriguez Pamela, Fernandez Patricia, Arango Celso and Mayoral Maria, PIENSA: Development of an Early Intervention Program for Adolescents With Early-Onset Psychosis and Their Families, Adolescent Psychiatry 2012; 2 (3) . https://dx.doi.org/10.2174/2210676611202030229
DOI https://dx.doi.org/10.2174/2210676611202030229 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Putative Role of Brain Acetaldehyde in Ethanol Addiction
Current Drug Abuse Reviews Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design The Molecular Mechanisms and Rational Design of Anti-Diabetic Vanadium Compounds
Current Topics in Medicinal Chemistry Microwave Assisted Amination of 2-Chloro Azoles with Various Substituted Aryl Piperazines and Aryl Sulfonylpiperazines Under Neat Conditions
Current Microwave Chemistry Systemic Administration of Antipsychotic Asenapine Pre or Postnatal does not Induce Anxiety-like Behaviors in Mice
CNS & Neurological Disorders - Drug Targets A Comprehensive Review on the Ethnopharmacology, Phytochemistry, Pharmacology, and Toxicology of the Mandragora Genus; from Folk Medicine to Modern Medicine
Current Pharmaceutical Design Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design Editorial [Hot topic: Melatonin and Brain (Guest Editor: Dun-Xian Tan)]
Current Neuropharmacology Biological Activities of Three Extracts from Artedia squamata: A Study on Antioxidant and Enzyme Inhibitory Potential
Current Bioactive Compounds Matrix Metalloproteinase Dependent Cleavage of Cell Adhesion Molecules in the Pathogenesis of CNS Dysfunction with HIV and Methamphetamine
Current HIV Research The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence
Current Pharmaceutical Design Pitx2 Expression Promotes p21 Expression and Cell Cycle Exit in Neural Stem Cells
CNS & Neurological Disorders - Drug Targets Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Osteocalcin: A Protein Hormone Connecting Metabolism, Bone and Testis Function
Protein & Peptide Letters Mental Health, Risk Factors and Access to Care for Primary School Children in the Island of Mauritius
Adolescent Psychiatry Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design The Corticotropin-Releasing Factor (CRF) Family of Neuropeptides in Inflammation: Potential Therapeutic Applications
Current Medicinal Chemistry